Syndax Announces Participation in March Investor Conferences
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company focused on developing cancer therapies, has announced its participation in two major investor conferences in March 2025. The company's CEO Michael A. Metzger and management team members will attend the TD Cowen 45th Annual Health Care Conference in Boston on March 4, featuring a fireside chat at 3:10 p.m. ET, and the Barclays 27th Annual Global Healthcare Conference in Miami Beach on March 13, with a fireside chat scheduled for 8:30 a.m. ET.
Live webcasts of both presentations will be available on Syndax's website in the Investor section at www.syndax.com, where replays will also be accessible for a time.
Syndax Pharmaceuticals (Nasdaq: SNDX), un'azienda biofarmaceutica in fase commerciale focalizzata nello sviluppo di terapie per il cancro, ha annunciato la sua partecipazione a due importanti conferenze per investitori a marzo 2025. Il CEO dell'azienda, Michael A. Metzger, e membri del team dirigenziale parteciperanno alla 45ª Conferenza Annuale sulla Salute di TD Cowen a Boston il 4 marzo, con un incontro informale previsto per le 15:10 ET, e alla 27ª Conferenza Annuale Globale sulla Salute di Barclays a Miami Beach il 13 marzo, con un incontro informale programmato per le 8:30 ET.
Le dirette web di entrambe le presentazioni saranno disponibili sul sito web di Syndax nella sezione Investitori all'indirizzo www.syndax.com, dove saranno anche accessibili le registrazioni per un certo periodo.
Syndax Pharmaceuticals (Nasdaq: SNDX), una compañía biofarmacéutica en etapa comercial centrada en el desarrollo de terapias contra el cáncer, ha anunciado su participación en dos importantes conferencias para inversores en marzo de 2025. El CEO de la compañía, Michael A. Metzger, y miembros del equipo de gestión asistirán a la 45ª Conferencia Anual de Salud de TD Cowen en Boston el 4 de marzo, con una charla informal programada para las 3:10 p.m. ET, y a la 27ª Conferencia Anual Global de Salud de Barclays en Miami Beach el 13 de marzo, con una charla informal prevista para las 8:30 a.m. ET.
Las transmisiones en vivo de ambas presentaciones estarán disponibles en el sitio web de Syndax en la sección de Inversores en www.syndax.com, donde también se podrán acceder a las repeticiones durante un tiempo determinado.
신닥스 제약(Syndax Pharmaceuticals) (Nasdaq: SNDX)은 암 치료제 개발에 집중하는 상업 단계의 생명공학 회사로, 2025년 3월 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다. 회사의 CEO인 마이클 A. 메츠거(Michael A. Metzger)와 경영진 팀원들이 3월 4일 보스턴에서 열리는 TD 코웬 제45회 연례 건강 관리 회의에 참석하며, 오후 3시 10분(ET)에 화상 대화가 예정되어 있습니다. 또한 3월 13일 마이애미 비치에서 열리는 바클레이즈 제27회 연례 글로벌 건강 관리 회의에도 참석하며, 오전 8시 30분(ET)에 화상 대화가 예정되어 있습니다.
두 프레젠테이션의 라이브 웹캐스트는 www.syndax.com의 투자자 섹션에서 확인할 수 있으며, 일정 기간 동안 재생도 가능합니다.
Syndax Pharmaceuticals (Nasdaq: SNDX), une entreprise biopharmaceutique en phase commerciale axée sur le développement de thérapies contre le cancer, a annoncé sa participation à deux grandes conférences pour investisseurs en mars 2025. Le PDG de l'entreprise, Michael A. Metzger, et des membres de l'équipe de direction assisteront à la 45ème Conférence Annuelle sur la Santé de TD Cowen à Boston le 4 mars, avec un échange informel prévu à 15h10 ET, et à la 27ème Conférence Annuelle Mondiale sur la Santé de Barclays à Miami Beach le 13 mars, avec un échange informel prévu à 8h30 ET.
Des webdiffusions en direct des deux présentations seront disponibles sur le site de Syndax dans la section Investisseurs à l'adresse www.syndax.com, où les rediffusions seront également accessibles pendant un certain temps.
Syndax Pharmaceuticals (Nasdaq: SNDX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Entwicklung von Krebstherapien konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 angekündigt. Der CEO des Unternehmens, Michael A. Metzger, und Mitglieder des Managementteams werden am 4. März an der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston teilnehmen, wo um 15:10 Uhr ET ein informelles Gespräch stattfinden wird, und am 13. März an der 27. jährlichen globalen Gesundheitskonferenz von Barclays in Miami Beach, wo um 8:30 Uhr ET ein informelles Gespräch geplant ist.
Live-Webcasts beider Präsentationen werden auf der Website von Syndax im Investorenbereich unter www.syndax.com verfügbar sein, wo auch Aufzeichnungen für eine gewisse Zeit zugänglich sein werden.
- None.
- None.
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
- TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside chat on Tuesday, March 4, 2025, at 3:10 p.m. ET
- Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday, March 13, 2025, at 8:30 a.m. ET
A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
When is Syndax Pharmaceuticals (SNDX) presenting at the TD Cowen Health Care Conference?
Who will represent SNDX at the March 2025 investor conferences?
What investor conferences will Syndax Pharmaceuticals (SNDX) attend in March 2025?
How can investors access Syndax's (SNDX) presentations at the March 2025 conferences?
